To this end, we took advantage of a recently developed, CRISPR/Cas9-engineered MOLM13-TP53 isogenic human AML cell line model (Boettcher et al, 2019) as well as a newly generated isogenic AML cell line model (MV4-11), and tested the efficacy of CAR T-cells targeting common (CD33, CD117, CD123) AML cell surface antigens using flow cytometry-based in vitro killing assays, live-cell imaging, transcriptional profiling (mRNA-seq), CRISPR/Cas9-based gene editing in CAR T-cells, and a xenogeneic mouse model of AML. The gene discussed is TP53; the disease is acute myeloid leukemia.